WASHINGTON / WINDSOR, CANADA / MANILA, PHILIPPINES — November 12, 2026 — A senior executive of Canadian prescription drug supplier CANARX has been arrested in the United States as federal authorities investigate an alleged years-long scheme involving the importation of prescription medicines from overseas.
The arrest has intensified scrutiny of a growing part of America’s healthcare industry: companies promising employers and patients cheaper access to expensive medications by sourcing them outside the United States.
According to court records reviewed by CNBC, John Thomas Howard, CANARX’s treasurer and a director, was arrested on Sunday, November 8, on charges involving smuggling, conspiracy and alleged violations of federal drug-importation laws.
His brother, Bob Howard, the company’s president and a director, is also sought by federal authorities, according to an affidavit prepared by an investigator from the US Food and Drug Administration’s Office of Criminal Investigations.
The criminal allegations concern conduct between February 22, 2017, and April 15, 2026.
The case follows years of regulatory scrutiny.
In 2019, the FDA warned CANARX that its prescription fulfillment practices involved medicines that had not received the required US regulatory approvals.
The company has disputed the government’s interpretation of its activities.
Its general counsel, Joseph Morris, told CNBC that both Howard brothers deny the accusations and intend to challenge them.
But the controversy raises a larger question: As American patients and employers search for relief from soaring prescription drug prices, are some lower-cost medicine programs exposing consumers to legal and safety risks that they do not fully understand?
CANARX Executive Arrested as Federal Investigation Expands
The investigation centers on CANARX, a prescription medication services company headquartered in Windsor, Ontario.
John Thomas Howard was arrested after federal authorities accused him of involvement in an unlawful prescription drug importation operation.
According to CNBC, the arrest warrant lists allegations involving conspiracy, smuggling, unlawful drug importation and the introduction of misbranded medicines into interstate commerce.
Court records also identify his brother Bob Howard as a person sought in connection with the investigation.
At the time of CNBC’s November 11 report, Bob Howard had not been taken into custody.
No plea had been entered for John Thomas Howard, according to the report.
The allegations are serious, but they remain subject to judicial proceedings.
An arrest establishes that authorities have taken a suspect into custody; it does not establish guilt.
Likewise, being sought by investigators does not mean a person has been convicted.
The defendants are entitled to contest the allegations and receive the protections available under US law.
FDA Investigator Describes Alleged Importation Scheme
The criminal complaint is supported by an affidavit from Dustin Dobbs, a special agent with the FDA’s Office of Criminal Investigations.
The affidavit alleges that CANARX imported, or caused the importation of, prescription drugs into the United States in violation of applicable federal requirements.
The investigation covers more than nine years of alleged conduct.
However, the affidavit summarized in CNBC’s reporting does not identify every specific medication prosecutors believe was unlawfully imported.
It also does not establish that all medicines distributed through CANARX were counterfeit or medically unsafe.
These distinctions are essential.
A drug may be manufactured by a legitimate pharmaceutical company and lawfully sold in another country while still lacking the approval or labeling required for distribution in the United States.
US law distinguishes between those regulatory issues and the separate question of whether a particular product is fake, contaminated or otherwise defective.
The government’s legal case will depend on the specific transactions, medicines, regulatory requirements and evidence presented in court.
How CANARX Built Its Cross-Border Prescription Business
CANARX was founded in 2002 and operates from Canada.
The company has marketed itself as an international prescription provider serving American customers through employer-sponsored programs.
According to its published descriptions, it sources medicines from countries including Canada, the United Kingdom, Australia and New Zealand.
These countries have established pharmaceutical regulatory systems.
CANARX has argued that sourcing medications through regulated international channels allows patients to obtain legitimate products at lower prices.
But US regulators have questioned whether the company’s fulfillment arrangements comply with American drug laws.
The distinction between a medicine being approved overseas and approved for the US market is central to the dispute.
Approval by a foreign regulator does not automatically authorize commercial distribution of that product in the United States.
That remains true even when the medicine contains an active ingredient also used in an FDA-approved product.
Labeling, manufacturing, supply-chain and regulatory requirements may differ.
Why American Employers Turn to Alternative Funding Programs
CANARX operates within an industry that CNBC examined in its earlier RiskyRX investigation.
That investigation explored companies often described as alternative funding programs, or AFPs.
These programs offer employers methods of obtaining expensive specialty medicines outside conventional US pharmacy-benefit arrangements.
Specialty drugs can be extremely costly.
They may be required for chronic illnesses, cancer, autoimmune conditions or other serious medical needs.
Employers providing health benefits may face substantial spending when workers require these treatments.
Some alternative funding arrangements attempt to reduce those costs by sourcing medicines through different channels.
For employers, the appeal can be significant.
Lower medicine costs may reduce the overall expense of providing health coverage.
For employees, such arrangements may promise access to treatments they might otherwise struggle to afford.
However, savings do not automatically establish that every sourcing method is lawful or provides equivalent patient protections.
That is the question now confronting CANARX and the wider industry.
FDA Warned CANARX About Its Practices in 2019
The federal case did not emerge without prior regulatory scrutiny.
On February 26, 2019, the FDA issued a formal warning letter to CanaRx Services Inc. and associated operations.
The agency described concerns about the company’s role in facilitating the distribution of unapproved and misbranded prescription medicines to American consumers.
The FDA said CANARX worked with employers and foreign pharmacies to fulfill prescriptions.
According to the agency’s description, a patient would provide a prescription issued by a US healthcare professional.
The prescription could then be reissued under the direction of a foreign physician and filled by a pharmacy outside the United States.
The medicine would subsequently be shipped to the US patient.
The FDA argued that this process could substitute a foreign-market medicine for the FDA-approved product originally prescribed.
The regulator requested that the company stop distributing products that violated US requirements.
CANARX disputed aspects of the FDA’s interpretation and defended the legitimacy of its supply arrangements.
The 2019 warning is significant because it demonstrates that regulatory concerns had been formally communicated years before the latest arrest.
However, a warning letter is not a criminal conviction.
Why the FDA Says Foreign Prescription Drugs Can Create Safety Risks
The FDA’s concerns extend beyond administrative paperwork.
Medicines distributed outside approved US channels may not be subject to the same systems for labeling, inspection, recall management and supply-chain verification.
Some medications also have narrow therapeutic ranges, meaning relatively small differences in dosage or exposure may affect patient safety.
Other products are prescribed for serious conditions where treatment interruption or incorrect medication can carry substantial risks.
In its 2019 letter, the FDA identified examples involving treatments for HIV, cancer, organ transplantation and other medical conditions.
The agency also warned that differences in branding, packaging and dosage information could confuse patients.
But this does not mean every medicine manufactured or sold outside the United States is inherently unsafe.
Countries such as Canada, Australia and the United Kingdom operate legitimate pharmaceutical oversight systems.
The legal and medical issues concern whether specific products meet the applicable US requirements and whether the supply chain provides adequate protection for American patients.
The 2023 Drug Seizure Adds to the Regulatory History
CNBC reported that CANARX was involved in another FDA action during 2023.
According to correspondence obtained by the network, the agency seized a medication shipment that it believed could involve misbranded or potentially counterfeit products.
The seizure demonstrates that investigators continued examining the company’s activities after the 2019 warning.
However, the available report does not establish that all medicines supplied by CANARX were counterfeit.
Nor does the seizure alone establish that the Howard brothers committed the offenses alleged in the new criminal complaint.
Those questions must be decided through the applicable investigative and legal processes.
The distinction matters because regulatory suspicion, seizure of a shipment and a judicial finding of wrongdoing are separate events.
Gilead Sciences Files Separate Lawsuit Over HIV Medication
The federal case also intersects with a civil lawsuit involving pharmaceutical manufacturer Gilead Sciences.
Gilead has accused CANARX and other entities of improperly importing versions of Biktarvy, a prescription medicine used to treat HIV.
Biktarvy is a branded antiretroviral treatment.
The civil lawsuit raises questions about pharmaceutical distribution channels and the rights of manufacturers to control and monitor the sale of their medicines under applicable law.
In a statement provided to CNBC, Gilead welcomed federal efforts to protect the integrity of the American medicine supply chain.
However, the company’s lawsuit remains a separate legal matter.
Its allegations should not be treated as established facts merely because criminal charges have also been reported against CANARX executives.
Nor should the case involving Biktarvy be confused with other Gilead medicines that have separate regulatory approvals and distribution arrangements.
The Price of HIV Medicines Highlights the Affordability Debate
The controversy comes amid continuing international debate over the cost of important prescription medicines.
High drug prices can limit access even when effective treatments exist.
Manufacturers, governments and public-health organizations have pursued different solutions, including negotiated prices, insurance coverage and authorized generic manufacturing.
As WWC ONE MEDIA reported in its coverage of a lower-cost generic HIV-prevention injection receiving tentative FDA approval, licensing agreements can help expand access to more affordable medicines in eligible countries.
That development concerns lenacapavir, a medicine used for HIV prevention, not Biktarvy or the CANARX criminal complaint.
It illustrates an important distinction.
Authorized generic licensing and lawful regulatory pathways can expand affordability while maintaining oversight.
Unapproved commercial imports raise different regulatory questions.
The existence of an affordability problem does not eliminate requirements designed to protect patients.
America’s Healthcare Costs Help Explain the Demand for Cheaper Drugs
The CANARX case cannot be separated from the broader economics of American healthcare.
Prescription prices are one component of an expensive system that also includes insurance, hospital services, professional care and administrative costs.
As WWC ONE MEDIA examined in its report on America’s expanding healthcare economy and rising costs for patients, total US healthcare spending reached approximately US$5.3 trillion in 2024.
Employers face pressure to maintain affordable insurance coverage.
Workers face deductibles, copayments and other out-of-pocket expenses.
Expensive specialty medicines can place additional pressure on both groups.
These financial challenges help explain why alternative prescription programs attract interest.
But the search for lower costs also creates incentives for companies to use complex sourcing and reimbursement arrangements.
Regulators must determine whether those arrangements comply with the law and provide adequate patient protections.
US and European Regulators Are Increasing Scrutiny of Prescription Services
The CANARX investigation reflects a wider debate over how prescription medicines are supplied and marketed.
In the United Kingdom, advertising regulators have taken action against promotions that they considered inappropriate marketing of prescription-only weight-loss treatments.
As WWC ONE MEDIA reported in its coverage of rulings against Voy, Juniper and MedExpress, regulators examined whether promotional messages effectively advertised restricted medicines to the public.
Those advertising cases are unrelated to CANARX.
They arise under different legal systems and concern different conduct.
But they illustrate a common challenge: healthcare companies may innovate commercially faster than patients can understand the associated regulatory safeguards.
The central issue is ensuring that cost savings and convenience do not come at the expense of accurate information or appropriate medical oversight.
Trump’s International Drug-Pricing Agenda Adds Another Complication
US policymakers have been seeking ways to reduce what Americans pay for prescription medicines.
President Donald Trump’s administration has argued that Americans often pay higher prices for patented drugs than patients in other developed economies.
It has sought pricing arrangements intended to reduce that gap.
But changes to international drug pricing can have complex consequences.
As WWC ONE MEDIA reported in its analysis of proposals involving German pharmaceutical prices, research has questioned whether increasing prices overseas would necessarily produce equivalent savings for American patients.
That policy debate is separate from the allegations against CANARX.
Nevertheless, it helps explain why cross-border medicine prices remain politically sensitive.
Patients want affordable treatment.
Manufacturers seek returns on their investment.
Insurers and employers want to control spending.
Regulators must ensure that medicines reaching patients meet applicable safety and legal standards.
What Makes the CANARX Investigation Different?
The CANARX case brings several distinct issues together.
First, the accusations involve company executives rather than only a regulatory warning directed at a business.
Second, the alleged activity covers a period of more than nine years.
Third, the business model involves employer-sponsored access to medicines obtained internationally.
Fourth, the company had already received a formal FDA warning in 2019.
Finally, the company faces separate civil allegations from a major pharmaceutical manufacturer.
Together, these developments make the investigation significant for employers, insurers and pharmaceutical suppliers.
But they should not be combined into a conclusion of criminal guilt.
Each allegation must be evaluated according to the evidence and legal standards applicable to that proceeding.
Could Employer Health Plans Face More Scrutiny?
One possible consequence is increased examination of employers that participate in international prescription programs.
Companies offering employee health insurance may use outside administrators or vendors to provide access to expensive treatments.
Employers may believe such arrangements reduce costs and help workers obtain medication.
However, they may also need to assess regulatory compliance, sourcing documentation and patient protections.
The CANARX investigation could encourage some organizations to review their pharmaceutical purchasing arrangements.
That would be a potential industry response, not a confirmed regulatory requirement imposed on all employers.
No evidence reviewed for this article establishes that every employer using an alternative funding program has violated federal law.
The legality of particular arrangements depends on their structure and applicable regulations.
What Happens Next for John and Bob Howard?
The immediate next stage concerns the federal criminal process.
John Thomas Howard must have the opportunity to respond to the charges.
Bob Howard’s legal status may also change if authorities locate him or he appears voluntarily before the court.
Prosecutors will need to establish the facts required to support each charge.
The defense can challenge the government’s evidence and legal interpretations.
Investigators may also continue examining the company’s prescription fulfillment activities.
Meanwhile, Gilead’s separate civil action will proceed according to its own legal schedule.
The timing and outcome of these cases cannot be predicted from the arrest announcement alone.
There is no basis to describe either executive as convicted.
The Bottom Line: Cheaper Medicine Cannot Come at the Cost of Patient Trust
The arrest of CANARX treasurer John Thomas Howard marks a serious escalation in federal scrutiny of the company’s international prescription operations.
Authorities accuse the Canadian supplier’s executives of participating in a prolonged scheme involving unlawfully imported medicines.
The allegations follow a formal FDA warning in 2019, a reported 2023 seizure and a separate lawsuit involving an HIV treatment.
CANARX and the Howard brothers dispute the accusations.
The case will now test the government’s claims through the legal system.
But the larger economic problem remains unresolved.
Americans continue searching for affordable prescription medicines, while employers and insurers seek ways to manage rising healthcare costs.
International sourcing may appear attractive when prices differ sharply between countries.
However, genuine affordability must be balanced with reliable quality controls, proper regulatory authorization and patient safety.
The CANARX case is not proof that every overseas medicine is unsafe or that all alternative funding programs operate illegally. It is a reminder that the methods used to reduce drug costs must withstand legal and medical scrutiny.
As US authorities pursue CANARX executives over allegations of illegal prescription imports, could the investigation expose deeper problems in America’s search for cheaper medicines—or will the company’s defense challenge the government’s interpretation of cross-border pharmaceutical rules?
